In a report released on November 1, Jonathan Chang from Leerink Partners reiterated a Buy rating on Molecular Partners (MOLN – Research Report), with a price target of $10.00. Jonathan
In a report released on November 1, Jonathan Chang from Leerink Partners reiterated a Buy rating on Molecular Partners (MOLN – Research Report), with a price target of $10.00. Jonathan
For the full year 2024, at constant exchange rates, the Company reiterates its guidance for total expenses of CHF 65-70 million. Approximately CHF 7 million of this will be non-cash
Leerink Partners analyst Jonathan Chang maintained a Buy rating on Molecular Partners (MOLN – Research Report) on October 22. The company’s shares opened today at $6.24. According to TipRanks, Chang
Molecular Partners (MOLN) and Orano Med announced the oral presentation of the latest preclinical data supporting MP0712 as a Radio-DARPin Therapeutic, or RDT, at the European Assocation of Nuclear Medicine,
Molecular Partners (MOLN) announced the strengthening of a previously announced co-development agreement with Orano Med, a clinical-stage radiopharmaceutical company developing targeted alpha therapies with lead-212, or 212Pb, where both companies